Trends in Drug Resistance Prevalence in HIV-1-infected Children in Madrid: 1993 to 2010 Analysis

Pediatric Infectious Disease Journal

Volumn 31, Issue 11, 2012, Pages e213-e221

  de Mulder, Miguel ^a   Yebra, Gonzalo ^a   Navas, Adriana ^a   Martin, Leticia ^a   de Jose, Maria Isabel ^a   Navarro, Maria Luisa ^a   de Ory, Santiago Jimenez ^a   Gonzalez Granado, Ignacio ^a   Mellado, Maria Jose ^a   Ramos, Jose Tomas ^a   Holguin, Africa ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Children; Drug resistance; HIV 1; Spain; Susceptibility

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DNA POLYMERASE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; POL PROTEIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BASE PAIRING; BLOOD SAMPLING; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; SEROLOGY; SPAIN; SYMPTOM; TREND STUDY; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; SPAIN; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84867884177     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182678c7c     Document Type: Article

References (50)

1. World Health Organization. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. Progress report 2011. 2011 Available at: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. Accessed December 7
2. World Health Organization. AIDS Epidemic update:2005 UNAIDS and WHO. 2011 http://www.unaids.org/en/media/unaids/contentassets/dataimport/publications/irc-pub06/epi_update2005_en.pdf. Accessed December 7
3. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-465
4. Buchholz B, Beichert M, Marcus U, et al. German-Austrian recommendations for HIV-therapy in pregnancy and in HIV-exposed newborn—update 2005. Eur J Med Res. 2006;11:359-376
5. US Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2011 Available at: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed December 7
6. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22:973-981
7. Welch S, Sharland M, Lyall EG, et al.PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613
8. Boer K, England K, Godfried MH, et al.European Collaborative Study. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med. 2010;11:368-378
9. Fernández-Ibieta M, Ramos Amador JT, Guillén Martín S, et al. [Why are HIV-infected infants still being born in Spain?]. An Pediatr (Barc). 2007;67:109-115
10. Vigilancia epidemiologica del VIH/SIDA en España. Sistema de información sobre nuevos diagnósticos de VIH. Registro nacional de casos de SIDA. Actualización 30 de junio de 2011. 2011 Available at: http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/InformeVIHSida_Junio_2011.pdf. Accessed December 7
11. Palladino C, Bellón JM, Perez-Hoyos S, et al. Spatial pattern of HIV-1 mother-to-child-transmission in Madrid (Spain) from 1980 till now: demographic and socioeconomic factors. AIDS. 2008;22:2199-2205
12. European Migration Network. European Commission. European Migration Network status report 2010. 2011 Available at: http://emn.intrasoft-intl.com/Downloads/prepareShowFiles.do;jsessionid=EE43FDC24A034092F43489E734F4B471?entryTitle=EMN Status Report 2010. Accessed December 7
13. Judd A, Doerholt K, Tookey PA, et al.Collaborative HIV Paediatric Study (CHIPS). National Study of HIV in Pregnancy and Childhood (NSHPC). Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918-924
14. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102
15. Sánchez JM, Ramos Amador JT, Fernández de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:863-867
16. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-1035
17. García-Merino I, de Las Cuevas N, Jiménez JL, et al. Pediatric HIV BioBank: a new role of the Spanish HIV BioBank in pediatric HIV research. AIDS Res Hum Retroviruses. 2010;26:241-244
18. de Mulder M, Yebra G, Martín L, et al.Madrid cohort of HIV-infected children. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. J Antimicrob Chemother. 2011;66:2362-2371
19. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4:e4724
20. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics. 2009;25:1197-1198
21. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156-163
22. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608-1618
23. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age; Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR. 1994;43(RR-12):1-10
24. Foster C, Judd A, Tookey P, et al.Collaborative HIV Paediatric Study (CHIPS). Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS. 2009;23:159-166
25. European Center for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe 2011 2011 Available at: http://ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf. Accessed December 7
26. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr. 2006;42:614-619
27. Holguín A, de Mulder M, Yebra G, et al. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res. 2008;6:327-334
28. Yebra G, de Mulder M, Martín L, et al.Cohort of the Spanish AIDS Research Network (CoRIS). Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol. 2012;50:407-413
29. Zhang M, Foley B, Schultz AK, et al. The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology. 2010;7:25
30. Descamps D, Chaix ML, Montes B, et al.ANRS AC11 Resistance Study Group. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother. 2010;65:2620-2627
31. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 2006;42:843-852
32. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13:4
33. Bousheri S, Burke C, Ssewanyana I, et al. Infection with different hiv subtypes is associated with CD4 activation-associated dysfunction and apoptosis. J Acquir Immune Defic Syndr. 2009;52:548-552
34. Yebra G, de Mulder M, Martín L, et al.Cohort of Spanish AIDS Research Network (CoRIS). Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). Antiviral Res. 2011;89:19-25
35. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther (Lond). 2004;9:695-702
36. Chaix ML, Descamps D, Wirden M, et al.ANRS AC11 Resistance Group. Cohort PRIMO ANRS CO 6. FHDH ANRS CO4 Study Groups. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009;23:717-724
37. Yebra G, de Mulder M, Pérez-Elías MJ, et al. Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS ONE. 2011;6:e26757
38. Wittkop L, Günthard HF, de Wolf F, et al.EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-371
39. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087-1088
40. Delaugerre C, Chaix ML, Warszawski J, et al. [HIV-1 drug resistance in French infected-children: from newborn to adolescent]. Arch Pediatr. 2007;14:298-302
41. Delaugerre C, Chaix ML, Blanche S, et al.ANRS French Perinatal Cohort. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009;6:85
42. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr. 2003;32:292-297
43. Chakraborty R, Smith CJ, Dunn D, et al.Collaborative HIV Paediatric Study. UK Collaborative Group on HIV Drug Resistance. HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 2008;27:457-459
44. Ammaranond P, Sanguansittianan S. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam Clin Pharmacol. 2012;26:146-161
45. Delaugerre C, Warszawski J, Chaix ML, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol. 2007;79:1261-1269
46. Castro H, Judd A, Gibb DM, et al.Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011;377:1580-1587
47. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2011:113-139 Available at: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed December 7, 2011
48. Palladino C, Briz V, Policarpo SN, et al. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2010;29:563-566
49. Salazar JC, Cahn P, Yogev R, et al.PACTG 1051/BI Study Team. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS. 2008;22:1789-1798
50. Bologna R, Rugina S, Cahn P, et al. Safety and efficacy of darunavir co-administered with low-dose ritonavir in treatment-experienced children and adolescents at week 24. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008. Boston, MA Abstract 78LB